search
Back to results

Acetazolamide for Treatment Resistant Schizophrenia (APTS)

Primary Purpose

Schizophrenia, Schizo Affective Disorder

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Acetazolamide
Placebo
Sponsored by
Vishwajit Nimgaonkar, MD PhD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Schizo Affective Disorder, acetazolamide

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Written informed consent.
  • Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
  • PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
  • Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study.
  • Not participating in another randomized controlled clinical trial (RCT).

Exclusion Criteria:

  • Substance abuse in the past month/dependence past 6 months, (except nicotine).
  • History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
  • Pregnancy.
  • Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
  • Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
  • Intellectual disability as defined in DSM 5.

Sites / Locations

  • University of PittsburghRecruiting
  • St John's Medical College HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Acetazolamide

Placebo

Arm Description

acetazolamide capsules

Identical gelatin capsules

Outcomes

Primary Outcome Measures

Change in positive symptoms
Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (minimum score = 7, maximum score = 49)

Secondary Outcome Measures

Clinical Severity
Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 30 Items, (minimum score = 7, maximum score = 210)
Clinical Severity
Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (minimum score = 7, maximum score = 49)
Cognition
Trail Making Test (TMT) 86: This test estimates attention, working memory and executive function.
Clinical Severity
"Clinical Global Impression - Severity" (CGI-S). The CGI-S is a 7-point scale that rates the severity of the patient's illness at the time of assessment. The minimum score is 1 and the maximum score is 100. Scores which are lower in value indicate greater severity of illness. Higher scores indicate less severe illness.
Social Function
"Sheehan's Disability Scale" (SDS). The SDS is a self-report is a self-report tool that assesses functional impairment in work/school, social and family life with a 10-point visual analogue scale. The minimum score is 0 and the maximum score is 10. Scores which are lower in value indicate better outcomes with less disability. Higher scores indicate more severe illness with greater disability.
Global Assessment of Function
"Global Assessment of Function" (GAF). The GAF is an assessor reporting tool that assesses level of functioning on a 1 to 100 point scale. The minimum score is 1 and the maximum score is 100. Scores which are higher in value indicate better outcomes with less disability. Lower scores indicate more severe illness with greater disability.
Measure of satisfaction with one's Quality of Life (Quality of Life Scale/QOLS)
The QOLS was originally a 15-item instrument that measured five conceptual domains of quality of life: material and physical well-being, relationships with other people, social, community and civic activities, personal development and fulfillment, and recreation. After descriptive research that queried persons with chronic illness on their perceptions of quality of life, the instrument was expanded to include one more item: Independence, the ability to do for yourself. Thus, the QOLS in its present format contains 16 items. The QOLS is scored by adding up the score on each item to yield a total score for the instrument. Scores can range from 16 to 112. The QOLS scores are summed so that a higher score indicates higher quality of life. Average total score for healthy populations is about 90.
Socio-Economic Status
We will use a composite measure of educational attainment and pretax family (household) income based on the Hollingshead Redlich 4-factor index. The Hollingshead Four Factor Index of Socioeconomic Status is a survey designed to measure social status of an individual based on four domains: marital status, retired/employed status, educational attainment, and occupational prestige. The participant's education code is obtained education code is rated on a 7-point scale that lists highest grade completed. The participant's occupational code is rated on a 9-point scale. SES=0.5X education score+0.3Xincome score+ 0.3X occupation score.
Side Effects
We will make a list of side effects for CGY noted in the Drug Formulary. This list will be a comprehensive listing of possible side effects by body system, grading both the frequency and severity of the symptoms. Frequency (days per week): Severity: 0 = Absent = 1-2 days 1 = mild, does not interfere with functioning = 3-4 days 2 = moderate, some interference with functioning = 5-7 days 3 = severe, functioning is significantly impaired Frequency scores can range from 0 to 3, with higher scores equaling higher frequency. Severity scores can range from 1 to 3, with higher scores equaling greater severity.

Full Information

First Posted
December 15, 2020
Last Updated
January 4, 2023
Sponsor
Vishwajit Nimgaonkar, MD PhD
Collaborators
Stanley Medical Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT04887792
Brief Title
Acetazolamide for Treatment Resistant Schizophrenia
Acronym
APTS
Official Title
A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 1, 2022 (Actual)
Primary Completion Date
January 31, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Vishwajit Nimgaonkar, MD PhD
Collaborators
Stanley Medical Research Institute

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Detailed Description
Schizophrenia (SZ) afflicts over 21 million people worldwide. Persons with SZ have a 10% suicide rate and their lifespan is curtailed by over 25 years. There is an urgent need for efficacious antipsychotic drugs (APDs), particularly, second line drugs, because only 30-40% of APD-treated patients attain remission and 30% of patients show little or no response. Currently, Clozapine is the only reliable second line APD, but it can cause serious blood dyscrasias. To fill the void, the investigators have conducted systematic reviews of prior data and in silico searches. In a prior double-blind crossover randomized placebo-controlled trial (RCT), adjunctive Acetazolamide (ACZ) caused ~20% improvement in positive and negative symptom scores when added to APDs among partially-responsive patients with SZ (ACZ 2G/day). No patients dropped out. The RCT is supported by several other open trials. ACZ also reduces weight, thus it could combat weight gain, a common APD side effect. Independently, our systematic in silico strategy based on protein networks and gene expression profiles also identified Acetazolamide (ACZ) as a repurposable drug for SZ. ACZ crosses the blood-brain barrier. It is used to treat CNS diseases such as refractory seizures and idiopathic intracranial hypertension. Used for over 50 years, its side effects (SE) and adverse effects (AE) are well known and are manageable. It is a potent, specific inhibitor of carbonic anhydrase (CA), which catalyzes the conversion of CO2 to HCO3- and H+. CA is localized to pre-synaptic terminals and glial cells. It modulates GABAergic excitation, long-term synaptic transformation, attentional gating of memory storage and cerebrospinal fluid formation. Post-mortem brain and serological studies show raised CA levels in patients with psychotic/mood disorders. Several APDs also inhibit CA. The investigators thus postulate brain CA inhibition as the therapeutic target for ACZ in SZ. The investigators propose a double-blind, crossover RCT for SZ using adjunctive ACZ. To maximize the risk/benefit ratio, the investigators will enroll inpatients and outpatients with treatment resistant SZ (trSZ) who meet defined criteria (N=60 RCT completers). ACZ or placebo will be added to prescribed APDs for 8 weeks utilizing the Sequential Parallel Comparison Design to maximize power. The investigators have extensive experience with RCTs. The investigators will ensure timely recruitment by approaching a large group of patients we serve, across 2 sites. If ACZ is beneficial, in future studies the investigators will pursue its implementation for trSZ, and seek variables associated with treatment response.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia, Schizo Affective Disorder
Keywords
Schizophrenia, Schizo Affective Disorder, acetazolamide

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Crossover Assignment
Model Description
This study will be a randomized placebo-controlled sequential parallel comparison design (SPCD).
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Participant, care providers, Investigators and assessors will all be blinded. Study staff responsible for randomization will be unblinded.
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Acetazolamide
Arm Type
Active Comparator
Arm Description
acetazolamide capsules
Arm Title
Placebo
Arm Type
Active Comparator
Arm Description
Identical gelatin capsules
Intervention Type
Drug
Intervention Name(s)
Acetazolamide
Other Intervention Name(s)
Diamox
Intervention Description
ACZ 250 mg/day in gelatin capsules will be administered initially and increased over 7-10 days to 2g/day.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Identical gelatin capsules will be prepared by filling with inert excipients.
Primary Outcome Measure Information:
Title
Change in positive symptoms
Description
Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (minimum score = 7, maximum score = 49)
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Clinical Severity
Description
Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 30 Items, (minimum score = 7, maximum score = 210)
Time Frame
24 weeks
Title
Clinical Severity
Description
Clinical Severity as determined by the Positive and Negative Syndrome Scale (PANSS) positive symptom subscale. The PANSS is a standardized, clinical interview that rates the presence and severity of positive and negative symptoms, as well as general psychopathology for people with schizophrenia within the past week. Symptom severity for each item is rated according to which anchoring points in the 7-point scale (1 = absent; 7 = extreme) best describe the presentation of the symptom. 7 Items, (minimum score = 7, maximum score = 49)
Time Frame
24 weeks
Title
Cognition
Description
Trail Making Test (TMT) 86: This test estimates attention, working memory and executive function.
Time Frame
24 weeks
Title
Clinical Severity
Description
"Clinical Global Impression - Severity" (CGI-S). The CGI-S is a 7-point scale that rates the severity of the patient's illness at the time of assessment. The minimum score is 1 and the maximum score is 100. Scores which are lower in value indicate greater severity of illness. Higher scores indicate less severe illness.
Time Frame
24 weeks
Title
Social Function
Description
"Sheehan's Disability Scale" (SDS). The SDS is a self-report is a self-report tool that assesses functional impairment in work/school, social and family life with a 10-point visual analogue scale. The minimum score is 0 and the maximum score is 10. Scores which are lower in value indicate better outcomes with less disability. Higher scores indicate more severe illness with greater disability.
Time Frame
24 weeks
Title
Global Assessment of Function
Description
"Global Assessment of Function" (GAF). The GAF is an assessor reporting tool that assesses level of functioning on a 1 to 100 point scale. The minimum score is 1 and the maximum score is 100. Scores which are higher in value indicate better outcomes with less disability. Lower scores indicate more severe illness with greater disability.
Time Frame
24 weeks
Title
Measure of satisfaction with one's Quality of Life (Quality of Life Scale/QOLS)
Description
The QOLS was originally a 15-item instrument that measured five conceptual domains of quality of life: material and physical well-being, relationships with other people, social, community and civic activities, personal development and fulfillment, and recreation. After descriptive research that queried persons with chronic illness on their perceptions of quality of life, the instrument was expanded to include one more item: Independence, the ability to do for yourself. Thus, the QOLS in its present format contains 16 items. The QOLS is scored by adding up the score on each item to yield a total score for the instrument. Scores can range from 16 to 112. The QOLS scores are summed so that a higher score indicates higher quality of life. Average total score for healthy populations is about 90.
Time Frame
24 weeks
Title
Socio-Economic Status
Description
We will use a composite measure of educational attainment and pretax family (household) income based on the Hollingshead Redlich 4-factor index. The Hollingshead Four Factor Index of Socioeconomic Status is a survey designed to measure social status of an individual based on four domains: marital status, retired/employed status, educational attainment, and occupational prestige. The participant's education code is obtained education code is rated on a 7-point scale that lists highest grade completed. The participant's occupational code is rated on a 9-point scale. SES=0.5X education score+0.3Xincome score+ 0.3X occupation score.
Time Frame
24 weeks
Title
Side Effects
Description
We will make a list of side effects for CGY noted in the Drug Formulary. This list will be a comprehensive listing of possible side effects by body system, grading both the frequency and severity of the symptoms. Frequency (days per week): Severity: 0 = Absent = 1-2 days 1 = mild, does not interfere with functioning = 3-4 days 2 = moderate, some interference with functioning = 5-7 days 3 = severe, functioning is significantly impaired Frequency scores can range from 0 to 3, with higher scores equaling higher frequency. Severity scores can range from 1 to 3, with higher scores equaling greater severity.
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Written informed consent. Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose). PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions. Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study. Not participating in another randomized controlled clinical trial (RCT). Exclusion Criteria: Substance abuse in the past month/dependence past 6 months, (except nicotine). History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy. Pregnancy. Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma. Current or prior treatment with ACZ or history of hypersensitivity to ACZ. Intellectual disability as defined in DSM 5.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vishwajit L Nimgaonkar, M.D., Ph.D.
Phone
412-246-6356
Email
vishwajitNL@upmc.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Maribeth A Wesesky, BPS
Phone
4122957017
Email
weseskyma@upmc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Vishwajit L Nimgaonkar, M.D., Ph.D.
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maribeth A Wesesky, BPS
Phone
412-295-7017
Email
weseskyma@upmc.edu
First Name & Middle Initial & Last Name & Degree
Vinayak Sant, Ph.D.
First Name & Middle Initial & Last Name & Degree
Satish Iyengar, Ph.D.
First Name & Middle Initial & Last Name & Degree
Konasale Prasad, M.D.
First Name & Middle Initial & Last Name & Degree
Maribeth A Wesesky, BPS
First Name & Middle Initial & Last Name & Degree
Ian Conner, M.D.
First Name & Middle Initial & Last Name & Degree
Madhavi K Ganapathiraju, Ph.D.
Facility Name
St John's Medical College Hospital
City
Bangalore
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Smita N Deshpande, M.D.
Phone
(91)- 93126-54702
Email
smitadeshp@gmail.com
First Name & Middle Initial & Last Name & Degree
Triptish Bhatia, Ph.D.
Phone
(91)-11-23404363
Email
bhatiatriptish@yahoo.co.in
First Name & Middle Initial & Last Name & Degree
Ashok Mysore, M.D.
First Name & Middle Initial & Last Name & Degree
Anil Kakunje, M.D.
First Name & Middle Initial & Last Name & Degree
Smita Deshpande, M.D.

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
No individual data will be shared.

Learn more about this trial

Acetazolamide for Treatment Resistant Schizophrenia

We'll reach out to this number within 24 hrs